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SURGICAL ablation of the adrenals, ovaries and hypophysis has been tested as
a method of inducing remissions in breast cancer patients. About one third of
the patients so treated receive some benefit from such surgery. In an effort to
determine preoperatively which patients would benefit from such surgery, a
number ofresearch groups have studied the urinary excretion of various hormones
in breast cancer patients (Huggins and Dao, 1954; Loraine, Strong and Douglas,
1957; Kushinsky, Kotin, Crawley and Wu, 1960; Bulbrook, Greenwood and
Hayward, 1960). By measuring a wide range of urinary steroid metabolites,
the latter workers concluded that the only difference between the non-responsive
and responsive patients was that the former group excreted more 17-hydroxy
corticosteroids and less aetiocholanolone and androsterone than the responsive
patients. There are two ways to account for this. In patients with hormone
independent tumours (non-responsive) there may be a disturbance in the andro-
gen and corticosteroid metabolism such that more 17-hydroxy corticosteroids are
produced at the expense ofandrogen. The second possibility is that the disturbed
steroid metabolism of the non-responsive women predisposes them to develop
hormone independent mammary tumours.
One way ofinvestigating the first possibility would be to study the metabolism
of steroids in animals bearing experimentally implanted tumours and this paper
reports a study using this approach. The urinary steroid excretion represents a
balance between steroid synthesis and catabolism. In the oophorectomised
female the main site of steroidogenesis is the adrenal gland whilst catabolism
occurs mainly in the liver although extra hepatic catabolism can occur (Sweat
and Bryson, 1960; Cohen and Hume, 1960). In the human the main urinary
17-hydroxy corticosteroid is tetrahydrocortisol in a conjugated form, derived from
its parent compound cortisol by the action of two enzymes, A4 hydrogenase and
3-keto reductase (Tomkins, 1957). The main precursor of urinary aetiocholano-
lone and androsterone is probably androstenolone, although smaller amounts are
formed from androstenedione and testosterone (Van de Wiele and Lieberman,
1960).
Goodlad and Clark (1961) have studied the effect of implanted Walker 256
tumour on adrenal size and hepatic hydrogenase in rats and found that the tumour
induced adrenal hypertrophy and stimulated the total liver LA4 hydrogenase
activity. The present paper describes an effort to repeat this work and also toINFLUENCE OF WALKER 256 CARCINOSARCOMA
test the effect ofWalker 256 tumour on the hepatic metabolism ofandrostenolone.
Whether androstenolone is a naturally occurring steroid in the rat is not yet
certain but it has been identified by paper chromatographic methods in rat urine
(Ketz, Witt and Mitzner, 1961). Corticosterone was used in preference to cortisol
as the former is the main adrenal corticosteroid produced in the rat (Bush, 1953).
METHODS AND MATERIALS
150-200 g. hybrid rats were used. Unless otherwise stated, body weight
refers to total body weight less the weight of the tumour. For transplantation
of the tumour, non-necrotic tissue was minced (Cragie, 1949) and diluted with an
equal volume of sterile saline. The mince (0-2 ml.) containing about 100 mg.
wet weight of tumour were injected subcutaneously via the groin. Aseptic
conditions were maintained throughout the transplantation. Control animals
were injected with 0-2 ml. of saline.
Preparation of tissues
The animals were killed by a blow on the back of the neck, the liver rapidly
removed, weighed and minced in a hand mincer. Routinely 1 g. ofthis mince was
homogenised in 4 ml. ofice cold 0-25 M sucrose using a standard number ofstrokes
of the homogeniser. An aliquot of this 20 per cent w/v homogenate was further
diluted with sufficient cold 0-25 M sucrose to give a 7 per cent w/v homogenate.
For the experiments in which the tumour was homogenised, it was cut open and,
as far as possible, the non-necrotic regions removed with forceps for mincing and
homogenising.
Tumours were dissected free of skin and muscle and weighed. The adrenal
glands were dissected free from fat and weighed on a 50 mg. torsion balance.
Final incubation and extraction conditions
(a) A4 hydrogenase assay: This was essentially the same as Tomkins (1957).
Each incubation tube contained 04175 ,tmoles NADP, 2-5 ,umoles G-6-P, 20
/Imoles Tris-HClbuffer pH 7*4, 0-4jtmole corticosterone and 04 ml. 7 per cent w/v
homogenate in 0-25 M sucrose.
In both this and the androstenolone assay, the steroid was added as a solution
in 0-02 ml. propylene glycol and the reaction medium and homogenate were
preincubated separately for 2 minutes at 370 C. before mixing.
After 10 minutes, incubation at 370 C., the reaction was stopped by the addi-
tion of 8 ml. methylene dichloride. The organic and aqueous phases were
separated by centrifugation and the protein plus water layer discarded. The
methylene dichloride extract was then read at 240 mjt in a Unicam S.P. 500
spectrophotometer. An extraction control in which the steroid was added just
before extraction was carried out with each experiment. The amount of steroid
metabolised was obtained by subtracting the amount of steroid remaining after
incubation from the extraction control. One unit of A4 hydrogenase activity was
defined as a change in optical density of 0 01/minute.
(b) Androstenolone metabolism: Each tube contained 0.3 ,umoles NADP,
20 /amoles nicotinamide, 20 ,tmoles Tris-HCl buffer pH 7-4, 0.5 ,tmoles andro-
stenolone and 0-2 ml. 20 per cent w/v homogenate in 0'25M sucrose. After 40
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minutes, incubation at 370 C. the reaction was stopped by the addition of 5 ml.
methylene dichloride and an aliquot of the methylene dichloride taken to dryness
under nitrogen. The androstenolone content was measured by the Pettenkofer
reaction. The amount of androstenolone metabolised was calculated by sub-
tracting the amount of steroid remaining after incubation from the extraction
control. A calibration graph with androstenolone acetate as standard was
prepared for each experiment. One unit ofactivity was defined as the metabolism
of 1 jtg. androstenolone (measured as the acetate)/40 minutes.
All incubations were carried out in duplicate and each result is the mean of
6-8 experiments.
The Pettenkofer reaction was carried out by the method of Munson, Jones,
McCall and Gallagher (1948) as modified by Fotherby (1958).
The Blue Tetrazolium reaction was carried out according to Madder and Buck
(1952).
Androstenolone was purchased from British Drug Houses Ltd., and crystal-
lised once from ethanol before use. Corticosterone was kindly provided by
Professor W. Klyne from the Medical Research Council Steroid Reference Collec-
tion. Tris, NAD and dipotassium glucose-6-phosphate were purchased from
Sigma Chemical Co. Ltd., St. Louis, Missouri, U.S.A. NADP was purchased from
Bochringer and Son Ltd., Mannheim, West Germany. Methylene dichioride was
redistilled before use.
RESULTS
Rate of tumour growth
Therate oftumourgrowthwas veryvariable, depending onwhetherthe tumour
adhered to the peritoneal muscle or the skin (Talalay, Takano and Huggins, 1952),
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but the average time taken to reach a given tumour weight was as follows: 2 g.,
7 days; 5 g., 9 days; 10 g., 11 days; 15 g., 13 days; 20 g., 15 days. Talalay
et al. (1952) have reported that in rats, the growth rate of Walker 256 implanted
intramuscularly is independent of the sex of the host animal.
Liver size
Fig. 1 shows the variation of liver weight/100 g. body weight with the weight
of the tumour. In the male rats the liver size increase significantly (p <0-02)
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FIG. 3.-A4 Hydrogenase activity as a function ofthe weight of homogenate used in the incubations.
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in the smallest tumour group but does not increase further once the tumour
has reached 10 g. The females appear to be less susceptible to liver enlargement
as the weight increase does not become significant (p<0 05) until the tumour
reaches 10 g. The weight increase is about 10 per cent in both sexes.
Control animals receiving saline injections were killed at varying time intervals
up to 20 days after injection but no difference could be found in any of the para-
meters measured. Accordingly, all of the control results were combined as one
group.
Adrenal size
Fig. 2 shows the marked sex difference in the response of the adrenal gland to
an actively growing tumour. In the female the adrenal size remains constant
whereas in the male there is a highly significant (p<0-01) 25-40 per cent rise in
weight once the tumour reaches 10 g. (5 per cent of the body weight).
A4 Hydrogenase
Preliminary experiments with female rat liver were carried out to get the
correct conditions for measuring changes ofenzyme activity, and Fig. 3 shows that
under the conditions used, the enzyme is the rate limiting factor. Although
NADH2 can act as hydrogen donor if inorganic phosphate is present (Leybold
and Staudinger, 1962; McGuire, 1962) this effect is small, so NADPH2, generated
from NADP, G-6-P and endogenous G-G-P dehydrogenase was the only pyridine
nucleotide used in this assay. NADP concentrations in excess of ,tmole/ml.
were inhibitory. A concentration of 0-175 ,umoles NADP and 0 4 ,umoles corti-
costerone/05 ml. final incubation volume was used routinely. Routinely, 7 mg./
tissue/incubation tube was chosen for the assay.
It has been reported that the A4 hydrogenase activity of female rat liver is
located in the microsome fraction (Forchielli and Dorfman, 1956; Tomkins,
1957), but in the experiments reported here there was an appreciable loss of
activity if the homogenate was centrifuged at 7000 g for 10 minutes to remove
cell debris nuclei and mitochondria. Accordingly whole homogenates were used
routinely. This loss ofactivity is in agreement with the experiments ofDe Venuto
and Westphal (1961) on the metabolism of cortisol by subcellular fractions of rat
liver.
It should be emphasized that in using this assay procedure, it is only the
"metabolising potential " of the tissue that is being measured as the enzyme has
been deliberately saturated with NADPH2 and there is no reason to believe that
such a condition prevails in vivo.
Fig. 4 and 5 show that A4 hydrogenase activity expressed per g. wet weight of
liver and per whole liver/100 g. body weight respectively. Again, a sex difference
in the response to tumour growth is evident. In the males the effect is clear
cut with a significant rise (p <0 02) in enzyme concentration (/g. wet weight) and
total hepatic activity when the tumour reaches 5-10 g. In the females the pattern
is more complex, but no sustained rise in activity is evident although there is a
significant peak of activity (p <0 02) expressed on a /g. wet weight basis in the
5-10 g. tumour weight group.
In a few experiments an aliquot of the methylene dichloride extract was used
to estimate a-ketols by the blue tetrazolium reaction. There was no difference
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between the incubated tubes and the extraction controls, so it would appear that
under these conditions there is no reduction ofthe C-20 carbonyl group or removal
of the C-17 side chain.
The tumour itself did not show any A4 hydrogenase activity towards corti-
costerone or androstenedione. This was tested both with 7 mg. and 40 mg. of
tumour homogenate/incubation tube.
Anrsrostenolone metabolism
Table I shows the pyridine nucleotide requirements. For optimal conditions
NADP and nicotinamide are required but not G-6-P. This suggests that the
NADP is required in the oxidised form presumably for the oxidation of the 3/?
hydroxy group (Kochakian, Carroll and Uhri, 1957) and that there is sufficient
NADPH2 available from endogenous substrates for any reductive metabolism
such as 7 a (Starka and Kutova, 1962) or 16 a hydroxylation (Colas, 1962).
Fig. 6 shows that under the conditions employed, the enzyme is the rate
limiting factor. Routinely, 0*3 ,umoles NADP, 0*5 ,lmoles androstenolone and
40 mg. of tissue were used.
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FiG. 6.-Androstenolone metabolism as afunction ofthe weight ofhomogenate used in the incubations.
TABLE I.-Pyridine Nucleotide Requirements for the Metabolism of Androstenolone
by Rat Liver Homogenates
All incubation tubes contained 20 4Emoles Tris-HCl buffer pH 7 4, 0 5
/Lmoles androstenolone and 0-2 ml. 20 per cent w/v homogenate in 0-25M
sucrose. Final incubation volume 0-5 ml. The incubations were carried
out at 370 for 30 minutes in air.
Androstenolone
metabolised
jug.Ig. Additions tissue/hour
None . . 0
0 3,umoles NAD . 200
0 34umoles NAD + 20,moles nicotinamide * 700
0 3pmoles NADP . . . . . 600
0 3,moles NADP + 20,umoles nicotinamide 1,200
0 3,moles NADP + 20,umoles nicotinamide 900
+ 2 - 5 pmoles G-6-P
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No significant difference in the disappearance of androstenolone could be
detected between the control and tumour-bearing animals (Fig. 7 and 8) otherthan
a slight fall in the livers of female rats bearing very large tumours.
The tumour itself was unable to metabolise androstenolone.
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DISCUSSION
The results presented in this paper do not agree with those published by
Goodlad and Clark (1961). Superficially, their results with female rats agree with
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our results with males in that there was an increase in liver aind adrenal size anid
in total hepatic A4 hydrogenase. However, their results with the A4 hydro-
genase could be explained solely by the increase in liver size as the activity/g.
wet weight did not change. The experiments reported here indicate an increase
in activity/g. wet weight as well as per total liver. They also reported a 30 per
cent increase in liver and adrenal weight 30 hours after tumour implantation.
This is in marked contrast with the results presented here in which the female
adrenal size remained constant throughout the experiment and the male adrenals
didnot enlarge until the tumour had reached 10 g., about 11 days after implanta-
tion.
In reviewing the literature oIn the Walker 256 tumour there is ample evidence
that it does produce adrenal hypertrophy in male rats (Ball and Samuels, 1938;
Haven, Bloor and Randall, 1949; Begg, 1951) but, with the exception of Goodlad
and Clark (1961) and a paper by Sure, Theis and Harrelson (1939) in which they
do not specify the sex of the animals used to measure adrenal size, no informatioil
could be found on the effect of Walker 256 tumour on the adrenals of female rats.
It is possible that the difference in results obtained by us and Goodlad and Clark
is due to the different experimental conditions used by the two groups, but in
view of the dramatic increase in adrenal anid liver size obtained bv those authors,
the increase in liver weight being greater than that obtained after partial hepatec-
tomy, it is felt that the results presented here give a better indication of the evenlts
associated with tumour growth than those reported by Goodlad and Clark.
It is interesting that Dalton (1944) found a sex difference in the loss of adrenal
lipids in micewith some but not all the tumours he tested. With the tumours
that did show a sex difference, the effect on the male adrenals was always larger
than on the female. Adams (1959, 1960) has suggested that tumour homogenate
injections can counteract the effects of androgens on the intracellular distribution
of liver catalase. A similar mechanism may be in operation here since the removal
of androgen is known to cause adrenal enlargement in male rats (Yates, Herbst
andUrquhart, 1958). It is not clear at what level such antagonism might occur
but as the effect of Walker 256 on adrenal size is abolished by hypophysectomy
(Ball and Samuels, 1938) it is unlikely to be by direct actioil on the adrenal gland.
Urquhart, Yates and Herbst (1959) have suggested that the ability of hepatic
A4 hydrogenase to inactivate corticosteroids can control the size and output of
the adrenal gland via the hypophysis. Thus, any factor influencing the A4
hydrogenase would also influence the adrenal gland. In support of this idea is
the present observation that the rise in A4 hydrogenase activity precedes the
adrenal weight increase.
With regard to the steroid status of the whole animal, the elevated A4 hydro-
genase in males would indicate an elevated secretion and excretion of adrenal
corticoids (Urquhart et al., 1959); McGuire and Tomkins, 1959; Glenister and
Yates, 1961), although the question as to whether the enlarged adrenals often
seen in tumour-bearing animals are hyper- or hypoactive has not yet been settled
(Begg, 1958; Claus, Trunnel and Llaurando, 1962; Millar, Davis, Toal, Brooks
and White, 1962). Nothing is known about the relationship of androstenolone
metabolism to adrenal secretion, so no predictions can be made as to the excretion
of androstenolone metabolites. Similarly, no predictions can be made about
steroid excretion in females so that discussion about a possible relationship of this
work to humans with breast cancer is valueless.
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SUMMARY
The effect of Walker 256 carcinosarcoma on liver and adrenal weight and
hepatic metabolism of corticosterone and androstenolone in male and female
rats has been investigated.
The liver weight increased in both sexes whereas adrenal enlargement was
only noted in male animals. This enlargement did not become evident until the
tumour weight had reached 10 g. (5 per cent ofthe body weight). In the male rats,
the hepatic A4 hydrogenase activity was increased, both on a per g. wet weight
and per whole liver basis, before the adrenal enlargement. This would support
the idea that the hepatic metabolism of corticosteroids can influence adrenal size
and secretion. Because of the high variation in female rats, no clear-cut effect
could be detected on A4 hydrogenase activity in these animals.
No significant variation in androstenolone metabolism could be detected iI
either sex.
The authors are greatly indebted to Dr. G. F. Marrian, F.R.S., Dr. J. Craigie.,
F.R.S., and Dr. F. C. Chesterman for their help and advice throughout this work.
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